Results 171 to 180 of about 93,929 (247)

Aurora-A drives sorafenib resistance by scaffolding stress granule assembly via phase separation. [PDF]

Proc Natl Acad Sci U S A
Kong L, Zhong F, Yu F, Wang T, Wang G, Bai Y, Xia H, Pan Z, Liu M, Zhang Y, Feng R, Zhang J, Du Y, Zhang K, Guo J, Ruan K, Yang Z.   +16 more
europepmc   +1 more source

Phospho-JNK agonists show promising effects for the treatment of hepatocellular carcinoma. [PDF]

iScience
Kim W, Jin H, Miao P, Ozcan M, Liao X, Li M, Iqbal S, Sebhaoui J, Ashraf S, Belmen B, Turkez H, Boren J, Uhlen M, Shi X, Zhang C, Mardinoglu A.   +15 more
europepmc   +1 more source

C/EBP-β Mediates the Reversal of Sorafenib Resistance by Tunicamycin in Hepatocellular Carcinoma. [PDF]

J Hepatocell Carcinoma
Pang C, Chen J, Chu M, Chen J, Wang H, Miao H.   +5 more
europepmc   +1 more source

Cost-utility analysis of lenvatinib and sorafenib for the first-line treatment of unresectable hepatocellular carcinoma in Vietnam: Evidence from a lower-middle income country. [PDF]

PLoS One
Do TX, Nguyen HT, Nguyen PTL, Kieu MTT, Duong TV, Pham VNH.   +5 more
europepmc   +1 more source

Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer). [PDF]

Future Oncol
Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler OV, Bouattour M, Dao TV, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Kurland JF, Balaji K, Abou-Alfa GK.   +23 more
europepmc   +1 more source

Design, synthesis, and <i>in vitro</i> antiproliferative activity of novel 4-amino-6-phenoxyquinoline and 4,6-diphenoxyquinoline. [PDF]

RSC Adv
Al-Sheikh A, Abuoun M, Khalaf H, Albaz N, Zaytoun A, Abuarqoub D.   +5 more
europepmc   +1 more source

Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma. [PDF]

J Gastrointest Oncol
Ono A, Hayes CN, Kawaoka T, Tsuge M, Oka S.   +4 more
europepmc   +1 more source

Computational-experimental repurposing reveals synergistic sorafenib/hydroxychloroquine response in KRAS-mutant breast cancer. [PDF]

BMC Pharmacol Toxicol
Abdelwahab MM, Soliman M, Nassrallah A.
europepmc   +1 more source

Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies. [PDF]

MedComm (2020)
He P, Xie S, Xie K, Gao F, Cai Y, Huang Y, Liu C, Wu H, Lyu Y, Lan T.   +9 more
europepmc   +1 more source

Is PD-1/PD-L1 inhibitor plus bevacizumab superior to sorafenib as first-line treatment for advanced hepatocellular carcinoma? A pooled analysis of four phase 3 RCTs. [PDF]

BMC Gastroenterol
Zhong Q, Li H, Hu W, Li Z, Hu Z.
europepmc   +1 more source